Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129060 | 0.86 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL9381822 | 0.82 | TSHR (0.47) | MAPTALDH1A1NPC1RAB9ATSHR | |
| SCHEMBL126729 | 0.79 | — | — | |
| SCHEMBL128202 | 0.75 | CA12 (0.38) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL19028033 | 0.71 | TSHR (0.37) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL17056166 | 0.69 | ALDH1A1 (0.42) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL837325 | 0.69 | ALDH1A1 (0.55) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL7207826 | 0.69 | ALDH1A1 (0.39) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL108390 | 0.69 | MAPT (0.50) | MAPTALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL19028053 | 0.69 | CYP4F2 (0.34) | MAPTALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1786782-A2 | BISARYL-SULFONAMIDES | Amgen Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | claimed |
| WO-2006020830-A2 | BISARYL-SULFONAMIDES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| CN-102802419-A | HEDGEHOG inhibitors | SELEXAGEN THERAPEUTICS INC | 2012-11-28 | — | — | CN | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1786782-A2 | BISARYL-SULFONAMIDES | Amgen Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006020830-A2 | BISARYL-SULFONAMIDES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | MAPT 4602/4885ALDH1A1 2237/4885NPC1 1084/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | MAPT 4602/4885ALDH1A1 2237/4885NPC1 1084/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | MAPT 4877/4885ALDH1A1 580/4885NPC1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.